NPS Pharmaceuticals, Inc., President and Chief Executive Officer
Francois Nader, MD, has been President, Chief Executive Officer and a member of the Board of Directors of NPS Pharmaceuticals since 2008. During his tenure, Dr. Nader transformed NPS into a leading global biotechnology company focused on pioneering and delivering innovative therapies that transform the lives of patients with rare diseases worldwide. NPS’ lead product, Gattex® (US)/Revestive® (EU) for adult Short Bowel Syndrome, was approved in the US and Europe in 2012. NPS has also developed Natpara® for hypoparathyroidism and submitted its Biologic License Application to the U.S. Food and Drug Administration in October 2013. Recognizing his role in transforming NPS into a successful life sciences company, Dr. Nader was the recipient of the 2013 Ernst & Young National Entrepreneur Of The Year® Award in the Life Sciences category. This award is regarded as the world’s most prestigious business award for entrepreneurs.
Dr. Nader is a 30-year veteran of the healthcare industry. He joined NPS in 2006 as Chief Medical and Commercial Officer, and was promoted to Chief Operating Officer in 2007. Prior to joining NPS Dr. Nader was a Venture Partner at Care Capital.
At Aventis and its predecessor companies, Dr. Nader served on the North America Leadership Team and held a number of executive positions including Senior Vice-President, Integrated Healthcare Markets; Senior Vice-President, North America Medical and Regulatory Affairs; and Vice-President US Medical Affairs and Global Health Economics and Outcome Research. Previously, Dr. Nader led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc in France.
Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee. Dr. Nader is chairman of the Board of Trustees for BioNJ. He is also a member of the boards of the Biotechnology Industry Organization (BIO) and the New Jersey Chamber of Commerce.